Urology news for Wednesday, November 18, 2026
Top 5 in urology
- AUA/SMSNA update ejaculation disorders guideline with new statements on PDE5i, clomipramine, HA injection Guideline · J Urol · 2026-11-18
The amended AUA/SMSNA Disorders of Ejaculation guideline adds an expert opinion statement on PDE5 inhibitors for premature ejaculation and new statements supporting daily or on-demand clomipramine and glans hyaluronic acid injection, with caveats.
Why it matters: Updates evidence-based options clinicians can discuss with patients for premature ejaculation, emphasizing shared decision-making.
More Men's health news - FDA device-report analysis flags higher serious injury and death rates for histotripsy vs thermal ablation Retrospective · Radiology · 2026-11-18
Analysis of FDA MAUDE reports found higher rates of serious injury (86% vs 20%) and death (14% vs 2%) among histotripsy adverse event reports compared with microwave/radiofrequency ablation over comparable 24-month postmarket periods.
Why it matters: Raises safety questions about early postmarket histotripsy use that warrant prospective evaluation; MAUDE reporting is passive and not denominator-adjusted.
More Technology and AI news - Positive margins after minimally invasive partial/radical nephrectomy tied to higher local recurrence Retrospective · Eur Urol Focus · 2026-11-18
In a cohort of 3812 patients with localized RCC, positive surgical margins after minimally invasive surgery were associated with markedly higher local recurrence (SHR 5.95) and atypical recurrence (SHR 9.02), an interaction not seen with open surgery.
Why it matters: Raises the question of whether margin status after minimally invasive nephrectomy warrants closer surveillance, hypothesis generating from a single retrospective cohort.
More Kidney cancer news - Obesity measures linked to higher prevalence of benign prostatic enlargement, evidence quality very low Meta-analysis · Eur Urol · 2026-11-18
A meta-analysis of 24 mostly cross-sectional studies found waist circumference over 90 cm and higher BMI associated with prevalent benign prostatic enlargement and moderate-to-severe LUTS, particularly in Asian men, with very low certainty of evidence.
Why it matters: Adds support for a possible link between adiposity and LUTS/BPE, though cross-sectional design limits causal inference.
More BPH and male LUTS news - CMS finalizes CY2027 Medicare Physician Fee Schedule with conversion factors down about 2% Policy · Centers for Medicare & Medicaid Services · 2026-11-17
The CY2027 Physician Fee Schedule final rule, released November 4, sets the conversion factor at $32.95 for qualifying APM participants (down 1.83%) and $32.63 for all other clinicians (down 2.31%).
Why it matters: Lower conversion factors reduce Medicare payment for urology services in 2027; practices should review budgets and coding before January.
Prostate cancer news
- Specific molecular alterations explain discordance between genomic and clinical risk in localized prostate cancer Retrospective · Clin Cancer Res · 2026-11-18
Across 287,145 patients, TP53, PTEN, AR activity and RB1 status were linked to discordance between Decipher Genomic Classifier and NCCN risk groups; adverse molecular features added prognostic information for distant metastasis in high-risk patients.
Why it matters: Suggests molecular feature profiling could refine risk stratification beyond genomic classifier scores alone in high-risk disease.
- Opioid-free anesthesia shows no significant benefit over opioid-based technique in prostatectomy RCT · World J Urol · 2026-11-18
In a 57-patient randomized trial, opioid-free anesthesia did not significantly reduce 24-hour postoperative oxycodone consumption or pain scores compared with remifentanil-based anesthesia during laparoscopic radical prostatectomy.
Why it matters: Suggests opioid-free protocols are not clearly superior for postoperative analgesia in this setting, though trial was underpowered for equivalence.
- Elevated neutrophil-lymphocyte ratio linked to worse survival on 177Lu-PSMA-617 therapy Retrospective · Prostate Cancer Prostatic Dis · 2026-11-16
In a two-institution retrospective analysis of 501 mCRPC patients treated with 177Lu-PSMA-617 after taxane therapy, a neutrophil-lymphocyte ratio above 3 at the first cycle was independently associated with worse survival, with persistently elevated NLR through cycle 2 linked to the poorest outcomes.
Why it matters: Raises the question of whether a simple blood ratio could help flag patients needing closer monitoring during PSMA radioligand therapy, but needs prospective validation.
- Systematic review underlying new ACS guideline summarizes benefits and harms of PSA screening Meta-analysis · Cancer · 2026-11-13
A systematic review of 29 publications, including 23 from six randomized trials (PLCO, CAP, ERSPC, Goteborg-1, Rotterdam Pilot 1, ProScreen) and four observational studies, found PSA screening was associated with reduced incidence of advanced/metastatic disease and, in some trials, reduced prostate cancer-specific mortality, though findings on mortality were inconsistent.
Why it matters: Provides the evidence base, drawn from a systematic review of RCTs and observational studies, behind the updated ACS PSA screening guideline, useful for shared decision-making conversations.
- Meta-analysis: active surveillance shows similar mortality to surgery, but watchful waiting worse Meta-analysis · Clin Genitourin Cancer · 2026-11-13
Across 12 studies (36,993 patients), active surveillance showed no significant difference in cancer-specific or all-cause mortality versus radical prostatectomy, though evidence was underpowered; watchful waiting was associated with significantly higher cancer-specific and all-cause mortality than surgery.
Why it matters: Suggests active surveillance and watchful waiting are not interchangeable, though the active surveillance comparison remains underpowered.
- PSMA total tumor volume outpredicts SUV and PSA for overall survival in large PET registry Retrospective · J Nucl Med · 2026-11-13
Among 13,893 prostate cancer patients in the PROMISE PET Registry split into development (n=9271) and validation (n=4622) cohorts, PSMA total tumor volume predicted overall survival in the validation cohort with a C-index of 0.78 (95% CI, 0.77-0.80), outperforming whole-body SUVmean (0.62; 95% CI, 0.61-0.64) and PSA at PET (0.71; 95% CI, 0.69-0.72), and performing similarly to PSMA total lesion uptake (0.78) and PSA times TTV (0.77).
Why it matters: A straightforward volumetric PSMA PET measurement may offer a more reliable way to stratify overall survival risk than SUV or PSA alone.
- FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA PET agent FDA action · OncLive · 2026-11-12
FDA granted Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA, a PSMA PET imaging agent, for detecting biochemically recurrent prostate cancer.
Why it matters: Designation may accelerate review of a new long-lived PSMA PET tracer option for recurrence imaging.
- NCCN adds ArteraAI post-prostatectomy test to guideline for biochemical recurrence risk News · Targeted Oncology · 2026-11-12
NCCN guidelines now include the ArteraAI test, an AI-based prognostic tool, for risk assessment after radical prostatectomy in the setting of biochemical recurrence.
Why it matters: Signals growing guideline incorporation of AI-based prognostic biomarkers into routine post-prostatectomy decision-making.
- ctDNA positivity before SBRT predicts rapid progression in oligoprogressive CRPC Retrospective · JAMA Netw Open · 2026-11-12
In this prespecified secondary analysis of the phase 2 TRAP trial, 19 of 77 evaluable patients (24.7%) were ctDNA-positive before SBRT; their 6-month progression-free survival was 21.1% versus 58.3% for ctDNA-negative patients, with median PFS of 3.0 versus 7.8 months (P = .003). Median overall survival was 27.2 months for ctDNA-positive patients and 33.6 months for ctDNA-negative patients.
Why it matters: Baseline ctDNA status may help identify oligoprogressive CRPC patients less likely to benefit from SBRT, supporting its potential use in selecting candidates for metastasis-directed therapy versus earlier systemic change.
- CT adds little over pelvic MRI for nodal staging in higher-risk prostate cancer, both poor vs pathology Retrospective · World J Urol · 2026-11-12
In 323 patients with unfavorable intermediate- or high-risk prostate cancer, MRI and CT showed only moderate agreement for nodal staging and both had low sensitivity (≤20%) versus surgical pathology; PSMA PET/CT performed better (AUC 0.86) in a subgroup with molecular imaging.
Why it matters: Raises the question of whether conventional CT adds meaningful nodal staging value when PSMA PET is available.
Bladder cancer news
- Cretostimogene reduces NMIBC recurrence risk by 68% in Phase 3 PIVOT-006, company reports Phase 3 RCT · Dealroom · 2026-11-16
CG Oncology announced topline results from its Phase 3 PIVOT-006 trial, reporting that cretostimogene reduced recurrence risk by 68% in NMIBC patients, with no patients discontinuing treatment due to related side effects. Full data and statistical details have not yet been disclosed.
Why it matters: A company-reported Phase 3 topline result suggests cretostimogene may offer a new intravesical option for NMIBC, pending full data disclosure and FDA review.
- Pooled phase 2/3 trials show 78% complete response with UGN-102 in recurrent low-grade NMIBC Retrospective · Urol Oncol · 2026-11-17
A pooled exploratory analysis of four phase 2/3 trials found 78.3% complete response at 3 months with UGN-102 in recurrent low-grade intermediate-risk NMIBC, with 79.7% remaining event-free at 12 months after response in the ATLAS/ENVISION subset. Within the ATLAS trial, UGN-102 showed higher 3-month CR (73.7% vs 51.5%) and higher 12-month event-free probability after CR (68.8% vs 44.2%) than TURBT.
Why it matters: Pooled phase 2/3 data add longer-term efficacy and safety evidence for UGN-102, an FDA-approved nonsurgical option for recurrent low-grade NMIBC.
- Adding trilaciclib to chemo-immunotherapy did not improve PFS in advanced urothelial cancer RCT · Clin Genitourin Cancer · 2026-11-17
In a randomized phase 2 trial of 92 patients with advanced urothelial carcinoma, adding trilaciclib to platinum chemotherapy plus avelumab maintenance showed modest myeloprotective effects but no improvement in progression-free survival (6.6 vs 6.1 months overall, HR 0.94).
Why it matters: Indicates trilaciclib added to standard first-line chemoimmunotherapy does not improve antitumor efficacy in advanced urothelial cancer.
- Continuous antibiotic prophylaxis after cystectomy tied to more resistant organisms, no infection benefit Retrospective · BJU Int · 2026-11-17
In a single-center retrospective cohort of 223 cystectomy patients, continuous oral antibiotic prophylaxis until stent removal showed no reduction in surgical site infection, UTI, or readmission compared to a short stent-removal course, but was linked to more Pseudomonas and other uncovered organism isolation.
Why it matters: Raises the question of whether prolonged antibiotic prophylaxis after cystectomy offers any benefit while potentially increasing resistant organism isolation.
- Biomarker-guided surveillance cuts cystoscopies in NMIBC without clear oncologic harm Meta-analysis · World J Urol · 2026-11-16
A meta-analysis of two randomized trials (DaBlaCa-15 and UroFollow, 606 patients, 590 in primary analyses) found biomarker-guided surveillance reduced cystoscopy use by 55.8% and 74.9% in the two trials respectively, with no significant difference in any recurrence (RR 1.04, 95% CI 0.77-1.41), high-grade recurrence or progression (RR 1.03, 95% CI 0.61-1.74), or progression to muscle-invasive/metastatic disease (RR 0.57, 95% CI 0.12-2.67); non-inferiority was not established.
Why it matters: Offers early randomized support for reducing cystoscopy burden in NMIBC surveillance, but confirmatory data are needed before changing guideline-based follow-up.
- FDA approves durvalumab with enfortumab vedotin for muscle-invasive bladder cancer FDA approval · FDA · 2026-11-13
FDA approved the perioperative combination of durvalumab (an immune checkpoint inhibitor) and enfortumab vedotin-ejfv for muscle-invasive bladder cancer.
Why it matters: Adds a new FDA-approved perioperative regimen option for muscle-invasive bladder cancer.
- Claims data: psychiatric diagnoses common after cystectomy regardless of diversion type Retrospective · Urology · 2026-11-15
In a TriNetX claims analysis of over 13,000 cystectomy patients, neobladder recipients had a transient excess of new mood disorder diagnoses in the first month (RR 1.81) that equalized with ileal conduit patients by 6 months; roughly a quarter of all patients had a new or recurrent psychiatric diagnosis by 5 years.
Why it matters: Hypothesis generating from claims data lacking clinical detail; suggests mental health needs after cystectomy are common and not clearly tied to diversion type long-term.
- Propensity-matched study inconclusive on histologic subtype risk in bladder-preserved NMIBC Retrospective · Clin Genitourin Cancer · 2026-11-15
In a propensity score-matched cohort of 456 NMIBC patients, those with histologic subtypes, divergent differentiation or neuroendocrine components had imprecise progression (HR 1.30, 95% CI 0.36-4.66) and recurrence (HR 0.59, 95% CI 0.27-1.31) estimates versus conventional urothelial carcinoma.
Why it matters: Raises the question of bladder-preserving approaches in variant histology NMIBC but the small event count and wide confidence intervals prevent any practice conclusion.
Kidney cancer news
- New MAGNIS score refines risk stratification for adjuvant pembrolizumab eligibility in ccRCC Retrospective · Urol Oncol · 2026-11-18
In 402 KEYNOTE-564-eligible patients, an integer-based score (tumor necrosis, age, M1NED, IVC thrombus, grade, pT4/pN+) stratified 4-year disease-free survival with moderate discrimination (C-index 67.8%).
Why it matters: Raises the question of whether a simple risk score could help individualize adjuvant pembrolizumab decisions, pending external validation.
- Meta-analysis finds checkpoint inhibitor combos benefit poor-risk ccRCC patients most Meta-analysis · Eur Urol · 2026-11-17
Pooling individual and aggregate data from four first-line immunotherapy trials in metastatic clear-cell RCC, survival benefit over sunitinib was concentrated in IMDC/CPI2 poor-risk patients (HR 0.51) with minimal benefit in favorable-risk patients (HR 0.98).
Why it matters: Suggests prognostic risk group may help identify which patients derive the most survival benefit from first-line IO combinations.
- CHMP recommends EU approval of belzutifan plus lenvatinib for advanced ccRCC Intl regulatory · Urology Times · 2026-11-13
The European Medicines Agency's CHMP has issued a positive opinion recommending approval of belzutifan combined with lenvatinib for advanced clear cell renal cell carcinoma.
Why it matters: If ratified by the European Commission, this would add a new combination option for advanced ccRCC in Europe.
- Robotic IVC thrombectomy linked to less blood loss and fewer complications than open surgery Retrospective · BJU Int · 2026-11-14
In a single-center retrospective cohort of 226 patients with renal tumor IVC thrombi (Mayo I-IV), robot-assisted thrombectomy was associated with less blood loss, shorter stay, fewer transfusions and complications than open surgery, with similar survival after adjustment and propensity matching.
Why it matters: Suggests robotic IVC thrombectomy may offer perioperative advantages over open surgery at experienced centers, without apparent oncologic tradeoff, though data are retrospective and single-center.
- Liver transplant team involvement tied to fewer complications in high-level IVC thrombectomy Retrospective · Urol Oncol · 2026-11-14
In a 36-patient single-center cohort of level III/IV renal tumor thrombectomy, cases with liver transplant team involvement had fewer major complications (11% vs 50%) and less hepatic dysfunction (0% vs 39%), but associations were attenuated and lost significance after adjusting for year of surgery.
Why it matters: Hypothesis generating only; in this small single center series the signal weakened after adjusting for year of surgery, so a causal benefit is unproven.
Upper tract urothelial carcinoma news
- Lynch syndrome carriers show 4.4% urothelial cancer rate, mostly upper tract Retrospective · JCO Precis Oncol · 2026-11-14
In a registry of 3,274 genetically confirmed Lynch syndrome carriers, 144 (4.4%) developed 224 urothelial carcinomas, over half in the upper urinary tract; MSH2/EPCAM variant carriers had higher risk (HR 4.43) than those with other MMR gene variants.
Why it matters: Raises the question of whether MSH2/EPCAM carriers warrant closer urothelial surveillance than other Lynch syndrome genotypes, pending prospective validation.
- Delphi consensus of 73 UTUC experts agrees on 32 of 40 statements for non-metastatic UTUC care Guideline · Nat Rev Urol · 2026-11-13
A two-round, web-based Delphi survey of 73 international UTUC experts (urologists and medical oncologists) rated 40 statements on diagnosis, staging, and treatment of non-metastatic upper tract urothelial carcinoma. Consensus was reached on 32 of 40 statements (80%) across both rounds, offering expert-informed guidance given limited high-level evidence in this disease.
Why it matters: Offers pragmatic expert consensus to help reduce practice variability in non-metastatic UTUC, an area with limited randomized trial evidence, though it is not a formal clinical guideline.
- Single-port robotic nephroureterectomy via lower anterior access feasible in multicenter series Retrospective · Eur Urol · 2026-11-07
In 47 patients across five centers, single-port retroperitoneal nephroureterectomy with bladder cuff excision via a single extraperitoneal incision achieved 76.7% pentafecta at 12 months, with 6% grade 3+ complications and 15% recurrence at median 12.3-month follow-up.
Why it matters: Describes an emerging single-port surgical technique for UTUC; comparative data against standard approaches are still needed.
- Commentary: pathogenic germline variants in urinary tract cancers are common but often missed Review · Renal & Urology News · 2026-11-04
A commentary piece discusses evidence that pathogenic germline variants are prevalent among patients with urinary tract cancers yet frequently go undetected on standard testing pathways.
Why it matters: Underscores the gap in germline testing uptake in urothelial cancers, consistent with prior reports of low testing rates in UTUC.
- Germline testing performed in under 5% of UTUC patients in claims analysis Retrospective · JCO Oncol Pract · 2026-10-31
A nationwide claims-based analysis of 4,783 patients with newly diagnosed UTUC found only 4.5% underwent germline testing, with no increase from 2015-2023, including just 5.6% of those diagnosed before age 50 who meet guideline criteria.
Why it matters: Raises the question of whether UTUC care pathways are failing to integrate germline evaluation despite guideline endorsement for Lynch syndrome screening; claims data cannot capture reasons testing was not ordered.
- Meta-analysis links neoadjuvant chemotherapy to better survival before nephroureterectomy in UTUC Meta-analysis · Eur Urol Oncol · 2026-10-27
Pooling 30 studies (2384 patients, mostly retrospective) on neoadjuvant chemotherapy for upper tract urothelial carcinoma, pathologic complete response occurred in 11% and downstaging in 20%; neoadjuvant chemotherapy was associated with HR 0.56 for overall survival and 0.47 for cancer-specific survival versus upfront surgery.
Why it matters: Adds support for a neoadjuvant chemotherapy approach in UTUC, though most included data are retrospective and immunotherapy evidence remains limited.
- UroVysion shows modest sensitivity but high PPV for UTUC in cytology-negative patients Retrospective · World J Urol · 2026-10-20
In a retrospective study of 1,256 patients with upper tract lesions and negative urinary cytology, UroVysion FISH had 66.9% sensitivity, 82.7% specificity, and 94.0% PPV for UTUC, and was associated with high-grade disease, lymphovascular invasion, and muscle invasion.
Why it matters: Raises the question of UroVysion as an adjunct when cytology is negative, though its low NPV limits its use for ruling out UTUC.
Testicular cancer news
- Testicular cancer incidence concentrated in high-HDI nations, mortality gap widening Study · Urology · 2026-10-28
GLOBOCAN-based analysis of 185 countries found 72,040 new testicular cancer cases and 9,068 deaths in 2022; incidence correlates with national development level while mortality-to-incidence ratio is far higher in lower-HDI regions, with cases projected to rise 22.7% and deaths 40% by 2050.
Why it matters: Highlights persistent global disparities in testicular cancer outcomes tied to treatment access rather than disease biology.
Adrenal tumors news
- Review questions need for universal biochemical workup of adrenal incidentalomas Review · Eur Urol Focus · 2026-11-01
This review argues that routine biochemical testing for pheochromocytoma may be omitted in homogeneous adrenal masses with 10 Hounsfield units or less on unenhanced CT, per 2023 European Society of Endocrinology guidance, while testing for mild autonomous cortisol secretion remains broadly recommended.
Why it matters: Offers a risk-stratified framework for adrenal incidentaloma workup that may reduce unnecessary biochemical testing in low-risk imaging phenotypes.
Penile and urethral cancer news
- Phase 2 trial registered: TROP-2 ADC plus PD-1 inhibitor for advanced penile cancer Trial registered · ClinicalTrials.gov · 2026-10-30
A newly registered single-arm phase 2 trial (SCOPE) plans to evaluate sacituzumab tirumotecan plus toripalimab as chemo-free second-line therapy in platinum-refractory advanced penile squamous cell carcinoma, a setting where current options shrink tumors in only 10-15% of cases. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2027-01-01; planned enrollment 31; single site.
Why it matters: Penile cancer has few second-line options; this trial addresses an unmet need with a TROP-2 targeted ADC combination.
Female pelvic medicine and neurourology news
- Phase 3 trial registered testing berobenatide for stress incontinence in women with obesity Trial registered · ClinicalTrials.gov · 2026-11-12
A planned 900-participant, roughly 63-week trial will evaluate the safety and effectiveness of berobenatide in women with stress urinary incontinence who also have obesity or overweight. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2026-11-17; planned enrollment 900.
Why it matters: A positive trial could add a pharmacologic option for SUI in a population where weight is a known risk factor and surgical candidacy may be limited.
Reconstruction and trauma news
- No significant volume-outcome link for AMS 800 sphincter after adjustment in European registry Prospective · Eur Urol Focus · 2026-11-18
Among 684 patients in the prospective SATURN registry, crude 1-year revision and complication rates varied by center volume, but no statistically significant association remained after multivariable adjustment for patient and procedure factors.
Why it matters: Suggests center volume alone may not explain AMS 800 outcome variation once case mix is accounted for.
- Longer oral mucosa grafts for urethroplasty linked to more donor-site morbidity Retrospective · World J Urol · 2026-11-15
Among 304 patients who underwent oral mucosa graft urethroplasty (115 with strictures ≤5 cm, 189 with strictures >5 cm), 21.1% reported at least one significant oral complication on follow-up questionnaires (up to 12 years). Oral numbness occurred in 17.1% overall, more often in the longer-stricture group (20.1% vs 12.2%), and discomfort while smiling or laughing was significantly more frequent in that group (7.4% vs 0.9%, p=0.01), with trends toward more pain, trismus, and eating difficulty that did not all reach statistical significance.
Why it matters: These findings support surgical planning that minimizes graft length and favors buccal-only harvest sites when feasible to limit long-term donor-site symptoms.
- Pump-preserving AUS revision feasible when pump is functioning normally Prospective · Urology · 2026-11-09
In a prospective single-center series of 60 artificial urinary sphincter revisions, surgeons preserved a normally functioning pump in all cases, with no pump-related complications and earlier device reactivation (2 weeks vs standard 6 weeks).
Why it matters: Suggests pump preservation may be a feasible option in selected AUS revisions to limit scrotal dissection and shorten reactivation time.
- Allium covered stents beat Memokath for radiation ureteral strictures but carry unique fistula risk Retrospective · World J Urol · 2026-11-09
Among 149 patients (205 ureteral units) treated for radiation-induced ureteral strictures, Allium stents showed higher 12- and 36-month primary success (75.9% vs 49.3% and 33.2% vs 23.2%) and cumulative success (96.3% vs 91.5% at 12 months, 64.0% vs 28.2% at 36 months) compared with Memokath stents, with median primary success duration of 30 vs 12 months (log-rank P < 0.001); ureteral fistulas occurred in 11 patients, exclusively in the Allium group.
Why it matters: For refractory radiation strictures, covered self-expandable stents may offer meaningfully longer patency than thermo-expandable stents, though the fistula signal tied to larger caliber and tandem stenting warrants careful sizing and patient selection.
- Meta-analysis: urethroplasty for post-BPH surgery bulbomembranous strictures shows 90% pooled patency Meta-analysis · BJU Int · 2026-11-01
A systematic review and meta-analysis of 417 patients from 9 observational studies found an overall pooled patency rate of 90% for urethroplasty after bulbomembranous strictures following BPH surgery, with patency around 87-94% depending on technique, though definitions of patency and continence varied widely.
Why it matters: Provides pooled benchmark patency rates for a challenging post-BPH stricture population, though heterogeneous outcome definitions and moderate-to-serious risk of bias limit certainty.
- Retrospective series reports outcomes after revision of difficult-to-catheterize continent channels Retrospective · Neurourol Urodyn · 2026-10-29
In a single-institution retrospective review of 45 adults undergoing 54 continent catheterizable channel revisions, 76% were free from reoperation at median 46-month follow-up, with success rates similar across suprafascial, subfascial, and replacement techniques.
Why it matters: Is hypothesis generating for channel revision technique selection given single-center retrospective design without randomized comparison.
Men's health news
- Eur Urol review updates classification systems and evidence gaps in male infertility Review · Eur Urol · 2026-11-13
A narrative review in European Urology summarizes new pathophysiological, endocrine (APHRODITE), and phenotypic classification systems for male factor infertility and highlights limited evidence for several add-on diagnostics and empirical therapies.
Why it matters: Offers urologists a current framework for classifying and evaluating male infertility beyond standard semen analysis.
- Company recalls supplement capsules with hidden sildenafil and acetaminophen FDA action · FDA · 2026-11-12
Game Changer Products LLC issued a voluntary nationwide recall of 10 Day Forecast Capsules after testing found undeclared sildenafil and acetaminophen, posing risks for patients on nitrates or with liver disease.
Why it matters: Patients using unregulated sexual-enhancement supplements may be unknowingly exposed to PDE5 inhibitors with drug interaction risks.
- Mail-in semen analysis kits show 93% completion within 16 weeks Prospective · J Urol · 2026-11-12
Among 35,444 patients using a national mail-in semen analysis platform, 93% completed testing within 16 weeks, with no meaningful differences by urbanization or neighborhood deprivation, though nearly a third tested before meeting guideline duration-of-infertility criteria.
Why it matters: Suggests mail-in semen analysis may reduce geographic and logistical barriers to male fertility evaluation.
Pediatric urology news
- Volumetric ratio may help select children for robotic nephrectomy in Wilms tumor Prospective · Eur Urol Oncol · 2026-11-08
In a prospective single-center series of 60 radical nephrectomies for presumptive Wilms tumor, about 40% (23/60) of children were selected for robot-assisted surgery using a new tumor-to-blood-volume ratio, with no significant difference in oncologic outcomes versus open surgery.
Why it matters: Suggests a volumetric selection criterion could help identify children suitable for robotic nephrectomy in Wilms tumor, pending external validation in larger cohorts.
- Review outlines when genetic testing is useful in CAKUT for urologists Review · Eur Urol Focus · 2026-11-08
A review discusses when genetic evaluation adds value in congenital anomalies of the kidney and urinary tract, emphasizing bilateral or severe anomalies, syndromic features, familial disease, and anatomy-function mismatch, while noting genetics should not drive surgical decisions alone.
- First multicentre study of Versius robot in pediatric urology reports interim safety data Prospective · J Pediatr Urol · 2026-11-06
In 60 procedures (mostly pyeloplasty) across three UK centres, 98.3% were completed robotically with one open conversion and no transfusions; median operative time was 195.5 minutes.
Why it matters: Early prospective data suggest the Versius platform may be feasible for pediatric minimally invasive urology, pending larger follow-up.
- Low-level pyuria tied to large jump in antibiotic prescribing for suspected pediatric UTI Retrospective · Pediatrics · 2026-11-06
Among 1150 pediatric ambulatory visits with urinalysis, 191 (16.6%) patients received antibiotics, and trace-to-low pyuria was associated with empiric antibiotic initiation (adjusted OR 6.62, 95% CI 3.72-11.79) versus no pyuria. This level of pyuria accounted for an adjusted attributable fraction of 17.0% (95% CI 10.3%-23.2%) for overtreatment in culture-negative children, compared with only 1.8% (95% CI 1.1%-2.4%) attributable fraction for treatment of culture-confirmed UTI.
Why it matters: Suggests that weighing degree of pyuria alongside age, symptoms, and risk factors rather than treating any pyuria as definitive could help reduce unnecessary antibiotic exposure in children evaluated for UTI.
- Thermocautery circumcision linked to far fewer early complications than bipolar sleeve or scalpel Retrospective · J Pediatr Urol · 2026-11-06
In a frequency-matched retrospective cohort of 31,100 boys, thermocautery guillotine circumcision had a complication rate of 0.6% versus 8.68% (bipolar sleeve) and 7.21% (scalpel guillotine), with zero bleeding events requiring suture ligation versus 15 and 25 respectively.
Why it matters: Raises the question of whether thermocautery technique reduces early circumcision complications, though retrospective design and single-center practice patterns limit causal inference.
- Nearly half of retractile testes ascend or need orchiopexy by age 7 in cohort study Prospective · J Urol · 2026-11-04
In a prospective single-institution cohort of 237 boys with retractile testicle(s) followed to median 7 years, cumulative incidence of testicular ascent was 47% and of orchiopexy was 57% by 84 months, with lower BMI and right-sided laterality associated with ascent.
Why it matters: Suggests boys with retractile testes warrant longer-term surveillance by a pediatric urologist rather than single-visit reassurance.
- New expert consensus aims to standardize surgery for pediatric kidney cancer Guideline · citybuzz - · 2026-11-03
A new expert consensus statement seeks to standardize surgical approach for childhood kidney cancer, according to the report.
Why it matters: A consensus statement may help reduce variability in surgical management of pediatric renal tumors.
- Multidisciplinary review addresses undescended testis management in medically complex children Review · J Urol · 2026-10-29
A narrative review by specialists across anesthesia, genetics, oncology, and urology examines how standard orchiopexy timing recommendations for undescended testis may need individualized reconsideration in children with syndromic or developmental conditions given elevated surgical risk.
Why it matters: Offers a framework for weighing surgical and anesthetic risk against fertility and oncologic benefit when managing undescended testis in medically complex children.
More urology news
- Phase 2 trial to test lenvatinib combinations in metastatic chromophobe RCC Trial opening · ClinicalTrials.gov · 2026-11-16
A new phase 2 trial (planned enrollment 40) will evaluate lenvatinib plus everolimus or lenvatinib plus pembrolizumab specifically in metastatic chromophobe renal cell carcinoma, a rare and treatment-resistant subtype.
Why it matters: Chromophobe RCC lacks dedicated prospective data; this trial could clarify options for a population underrepresented in prior RCC trials.
- Registered trial: phase 3 trial to test oral fosfomycin versus standard antibiotics for febrile UTI in men Trial registered · ClinicalTrials.gov · 2026-11-12
A planned 312-patient non-inferiority trial will compare oral fosfomycin-trometamol to fluoroquinolones or cotrimoxazole as step-down therapy for febrile UTI/prostatitis in men caused by E. coli, a use not previously studied prospectively. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2026-12-01; planned enrollment 312.
Why it matters: If non-inferior, fosfomycin could offer a lower-side-effect oral option for step-down therapy of febrile UTI in men.
Loading today's edition…